159 related articles for article (PubMed ID: 22806683)
1. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.
Ponnapakkam T; Katikaneni R; Suda H; Miyata S; Matsushita O; Sakon J; Gensure RC
Calcif Tissue Int; 2012 Sep; 91(3):196-203. PubMed ID: 22806683
[TBL] [Abstract][Full Text] [Related]
2. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model.
Katikaneni R; Ponnapakkam T; Matsushita O; Sakon J; Gensure R
Anticancer Drugs; 2014 Jan; 25(1):30-8. PubMed ID: 24025564
[TBL] [Abstract][Full Text] [Related]
4. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain.
Katikaneni R; Ponnapakkam T; Suda H; Miyata S; Sakon J; Matsushita O; Gensure RC
Int J Cancer; 2012 Sep; 131(5):E813-21. PubMed ID: 22130912
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone linked to a collagen binding domain promotes hair growth in a mouse model of chemotherapy-induced alopecia in a dose-dependent manner.
Katikaneni R; Ponnapakkam T; Seymour A; Sakon J; Gensure R
Anticancer Drugs; 2014 Aug; 25(7):819-25. PubMed ID: 24710191
[TBL] [Abstract][Full Text] [Related]
6. Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases.
Ponnapakkam T; Anbalagan M; Stratford RE; Rowan BG; Gensure RC
Anticancer Drugs; 2021 Apr; 32(4):365-375. PubMed ID: 33595947
[TBL] [Abstract][Full Text] [Related]
7. Treating osteoporosis by targeting parathyroid hormone to bone.
Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
[TBL] [Abstract][Full Text] [Related]
8. Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.
Ponnapakkam T; Katikaneni R; Nichols T; Tobin G; Sakon J; Matsushita O; Gensure RC
J Endocrinol Invest; 2011 Dec; 34(11):e392-7. PubMed ID: 21750397
[TBL] [Abstract][Full Text] [Related]
9. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
[TBL] [Abstract][Full Text] [Related]
10. Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation.
Vrahnas C; Pearson TA; Brunt AR; Forwood MR; Bambery KR; Tobin MJ; Martin TJ; Sims NA
Bone; 2016 Dec; 93():146-154. PubMed ID: 27686599
[TBL] [Abstract][Full Text] [Related]
11. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).
Alkhiary YM; Gerstenfeld LC; Krall E; Westmore M; Sato M; Mitlak BH; Einhorn TA
J Bone Joint Surg Am; 2005 Apr; 87(4):731-41. PubMed ID: 15805200
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy-associated plasma protein-A modulates the anabolic effects of parathyroid hormone in mouse bone.
Clifton KB; Conover CA
Bone; 2015 Dec; 81():413-416. PubMed ID: 26297833
[TBL] [Abstract][Full Text] [Related]
14. Therapy for alopecia areata in mice using parathyroid hormone agonists and antagonists, linked to a collagen-binding domain.
Katikaneni R; Gulati R; Suh D; Sakon J; Seymour A; Ponnapakkam T; Gensure R
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S61-2. PubMed ID: 24326563
[TBL] [Abstract][Full Text] [Related]
15. Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone.
Jay FF; Vaidya M; Porada SM; Andrukhova O; Schneider MR; Erben RG
Mol Cell Endocrinol; 2015 Dec; 417():158-65. PubMed ID: 26427650
[TBL] [Abstract][Full Text] [Related]
16. FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH.
Yuan Q; Sato T; Densmore M; Saito H; Schüler C; Erben RG; Lanske B
J Bone Miner Res; 2011 Sep; 26(9):2026-35. PubMed ID: 21590742
[TBL] [Abstract][Full Text] [Related]
17. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
Takeuchi Y
Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
[TBL] [Abstract][Full Text] [Related]
18. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
John MR; Widler L; Gamse R; Buhl T; Seuwen K; Breitenstein W; Bruin GJ; Belleli R; Klickstein LB; Kneissel M
Bone; 2011 Aug; 49(2):233-41. PubMed ID: 21514409
[TBL] [Abstract][Full Text] [Related]
19. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
Black DM; Bouxsein ML; Palermo L; McGowan JA; Newitt DC; Rosen E; Majumdar S; Rosen CJ;
J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
